Ro and Hims are two of the largest direct-to-consumer men’s telehealth platforms in the US. Both were founded in the same era (around 2017), both are well-capitalized public-market players, and both now offer overlapping product lines across hair loss, erectile dysfunction, weight loss, mental health, and dermatology. The differences in pricing and clinical approach are smaller than the marketing suggests. This ro vs hims comparison breaks down 2026 pricing across each major category, the clinical and customer-service track records, the safety points that actually matter, and which platform fits which use cases. The condensed answer: Ro is slightly stronger on hair-loss bundling and dermatology; Hims is slightly stronger on weight-loss promotional pricing and mental-health depth. Everything on both platforms is prescription-only and requires a clinician’s evaluation.
A note before the details: prices and promotions on both platforms change frequently, so treat every figure below as an estimate to verify on each company’s site. FMHC is not affiliated with Ro or Hims, and this comparison is independent.
Ro vs Hims by category — pricing in 2026
Hair loss: A Ro hair kit (finasteride + minoxidil + supplements) and a comparable Hims hair kit both land in roughly the same monthly range. Stripped to medication only, both are broadly similar for finasteride and for minoxidil. At the bundle level the pricing is essentially identical — confirm current numbers before signing up.
Erectile dysfunction: Both platforms start generic sildenafil at a low per-dose price, with generic tadalafil somewhat higher per dose, and “all-in-one” ED chew bundles in a monthly range at both. Per-dose pricing on generics is competitive and often beats retail, especially in quarterly bundles.
Weight loss: Both charge an initial visit fee plus an ongoing monthly membership or medication cost, with Hims historically running more aggressive promotional pricing. Both now deliver branded Wegovy and Zepbound at manufacturer-set pricing (see the GLP-1 section below for the important compounding changes).
Mental health: Hims offers a mental-health vertical (initial visit plus generic SSRIs in a monthly range); Ro does not currently offer a standalone mental-health vertical, so for mental health specifically, Hims is the only option between these two. See our Hims review and Ro review for individual platform breakdowns.
Ro vs Hims for hair loss
Hair loss is where the two platforms are most similar. Both offer generic finasteride 1mg and topical minoxidil 5%, both bundle medications with optional supplements like biotin and saw palmetto, and both ship on quarterly auto-refill cycles. The clinical evidence behind the underlying medications is the same — finasteride and minoxidil are FDA-approved with decades of supporting evidence per the NIH StatPearls review.
A word on finasteride: it is a prescription drug, not a cosmetic. Some men experience sexual side effects (reduced libido, erectile difficulty, ejaculatory changes), and a subset report symptoms that persist after stopping. There are also mood-related reports in the literature. Finasteride can lower PSA readings (relevant for prostate-cancer screening) and must not be handled by anyone who is or may become pregnant because of birth-defect risk. Discuss these cautions with the prescribing clinician rather than treating the drug as risk-free.
The slight edge goes to Ro for bundle simplicity — Ro’s hair-kit pricing tends to be more transparent and the upsells less aggressive than Hims. For pure hair-loss focus without competing product upsells, Keeps is generally a cleaner experience than either at similar pricing. See our Hims vs Keeps and Keeps vs Roman comparisons for the broader picture.
Ro vs Hims for ED
ED treatment is also nearly identical at the medication level. Both platforms prescribe generic sildenafil (Viagra), generic tadalafil (Cialis), and “off-the-tongue” chewable formulations that are the same active ingredients in different delivery formats. Per-dose pricing on generics is competitive and typically beats retail, particularly with quarterly bundles.
Safety that isn’t optional: PDE5 inhibitors like sildenafil and tadalafil must never be combined with nitrate medications (such as nitroglycerin for chest pain) or with certain “poppers,” because the combination can cause a dangerous, potentially fatal drop in blood pressure, per MedlinePlus. They also interact with some blood-pressure and prostate medications. ED can be an early warning sign of heart disease, so a real clinical evaluation matters — do not self-source these drugs from unregulated online sellers, where counterfeits are common. Used through a legitimate platform with a proper intake, both Ro and Hims screen for these contraindications.
Both platforms include educational content, dose adjustment based on response, and follow-up clinical access. Hims’s marketing has been slightly more aggressive on ED, while Ro’s branding skews younger and more clinical. For most ED patients, the clinical experience and outcomes are similar; the real comparison shifts to checkout flow, customer-service responsiveness, and branding preference.
Ro vs Hims for weight loss
Weight loss is where the two platforms differ most — and where the market changed dramatically. Hims has historically been more aggressive on promotional pricing, while Ro’s structure has leaned on a separate monthly membership. But the bigger story is what happened to compounded GLP-1 medications.
The compounded GLP-1 wind-down. During the 2022–2024 shortages of semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound), pharmacies were permitted to compound these drugs, and cheaper compounded versions drove a boom across telehealth. That window closed in 2025. The FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in early 2025, after which the enforcement grace periods for compounding pharmacies ended over the course of 2025 (verify exact dates). Both platforms shifted away from compounded GLP-1s toward branded Wegovy and Zepbound for new patients. Industry reporting indicates Ro largely exited compounded GLP-1s, while Hims and Novo Nordisk announced and then ended a branded-Wegovy partnership in 2025 amid a public dispute over Hims’s continued compounding and marketing — details that are fast-moving and should be confirmed against current company statements and news coverage before relying on them.
Why this matters for safety. With compounded supply curtailed, some consumers turn to gray-market or counterfeit “semaglutide” sold online. The FDA warns that unapproved and counterfeit GLP-1 products may contain the wrong drug, incorrect dosages, or harmful substances, and it has logged hundreds of adverse-event reports. Red flags include suspiciously low prices, no licensed-clinician oversight, spelling errors on labels, and damaged packaging. Buy only through state-licensed pharmacies and a real clinical intake — never from an unregulated seller or a “research chemical” site.
Branded medication pricing is set by manufacturers, not the platforms, so for branded GLP-1s the cost difference between Ro and Hims comes mostly from their membership and visit-fee structures. For comprehensive weight loss with structured coaching, neither Ro nor Hims is the strongest choice — Calibrate and Found offer more clinical depth. See our Ro vs Hims weight loss piece and Wegovy through Hims vs Ro for category-specific detail.
Ro vs Hims for dermatology
Both platforms offer dermatology services with custom-formulated topical products. Ro Skin’s tretinoin formulations and Hims’s anti-aging products use similar prescription-strength actives. Curology and Apostrophe have more refined dermatology-specific platforms — see our Curology review and Curology vs Apostrophe for those alternatives.
For patients already using Ro or Hims for hair loss or ED who want to add skincare to one account, both offer reasonable options. For dermatology as the primary focus, Curology tends to produce better outcomes for most patients.
Customer service and auto-renewal complaints
Both Ro and Hims have documented complaints about auto-renewal billing and difficulty cancelling subscriptions before the next shipment. Better Business Bureau filings and public forums carry similar volumes of complaints for both platforms.
Hims has slightly more documented complaints around subscription billing in recent years, partly because it markets more aggressively to new customers and converts more first-time subscribers. Ro’s complaint volume is lower in absolute terms but proportionally similar. Both have improved over time, but neither is flawless. Set calendar reminders before quarterly shipments and verify that a cancellation has actually been processed when ending a subscription.
Privacy and data practices
Both Ro and Hims handle protected health information and updated their privacy practices following the FTC’s 2023 enforcement actions against telehealth advertising data sharing. The GoodRx settlement raised the bar across the sector, and most major DTC telehealth companies have since tightened their tracking-pixel and advertising data-sharing practices.
Independent privacy assessments tend to rate both platforms as mid-pack for DTC telehealth — meaningfully better than the worst pre-2023 practices but not as careful as a traditional medical practice. Patients with strong privacy concerns should read each platform’s current privacy policy directly before signing up.
Frequently Asked Questions
Is Ro the same as Roman?
Yes. Roman was the original men’s brand under the Ro umbrella. The parent company operates the Roman vertical for men’s health alongside Ro Skin, Ro Hair, and other product lines. Hims is a separate company.
Which is cheaper, Ro or Hims?
The two platforms are nearly identical in pricing for hair loss, ED, and dermatology. Hims has historically run more aggressive promotional pricing on weight loss. For most categories the cost difference is small — and because promotions change often, verify current pricing on each site.
Does Ro or Hims accept insurance?
Neither platform is insurance, and neither bills insurance for the consultation fee. Some FDA-approved prescriptions can be sent to a retail pharmacy where your insurance may apply. Plan to pay out of pocket for memberships and for any compounded or branded medications purchased directly.
Which is better for weight loss?
The clinical model is similar at both. Hims has historically offered more aggressive promotional pricing. Both shifted toward branded medications in 2025–2026 as compounded GLP-1 availability ended. For comprehensive weight loss with coaching, Calibrate or Found are stronger alternatives. Whatever you choose, get GLP-1s only through a legitimate clinical channel.
Are Ro and Hims safe?
Both use licensed clinicians, licensed partner pharmacies, and standard privacy safeguards, and the medical care is legitimate at both. The real safety risks are self-sourcing prescription drugs from unregulated sellers, combining ED drugs with nitrates, and ignoring finasteride or GLP-1 cautions — all of which a proper clinical intake is designed to catch. Customer-service complaints about auto-renewal billing are real but separate from clinical safety.
TL;DR: Ro and Hims are more alike than different. For hair loss, ED, and dermatology the clinical experience and outcomes are essentially equivalent; Hims runs more aggressive weight-loss promotions and is the only one of the two with mental health, while Ro has slightly cleaner bundles and dermatology. Everything is prescription-only. The compounded GLP-1 era largely ended in 2025 once the FDA declared the semaglutide and tirzepatide shortages resolved, so both platforms leaned into branded Wegovy and Zepbound — verify each company’s current offerings. Never combine ED drugs with nitrates, take finasteride cautions seriously, and never self-source GLP-1s from unregulated sellers.
This is independent, informational content, not medical advice, and FMHC is not affiliated with Ro or Hims. Prices, promotions, and company partnerships change frequently — verify current details on each company’s site, and talk with a licensed clinician about what is appropriate for you.
Sources
- FDA — FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
- MedlinePlus — Sildenafil (nitrate contraindication and cautions)
- MedlinePlus — Finasteride
- NIH StatPearls — Minoxidil
- FTC — GoodRx enforcement action (2023)
- Ro and Hims company websites — current pricing and product offerings (verify; details change frequently)